Funded Project Details - FY2021
|Title:|| Design of Novel Non-catalytic Substrate-Selective p38 MAPK Inhibitor to Treat ARDS|
Jeffrey D. Hasday
|Congressional District Code:
||Biomedical Laboratory R&D
|| July 2018 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Acute Respiratory Distress Syndrome (ARDS) is a complication of serious infections and trauma and an important source of morbidity and mortality in Veterans and the general population. Despite improvements in supportive care, no pharmaceutical therapies have been developed and mortality remains over 40%. Although preclinical studies support pharmacologic inhibition of p38 mitogen-activated protein kinase (MAPK) to treat a range of inflammatory diseases, including ARDS, the currently available p3...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.